ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation

Transfusion Medicine and Hemotherapy

Volumn 43, Issue 1, 2016, Pages 3-12

  Worel, Nina ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ABO incompatible; Hematopoietic stem cells; Transplantation

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; ENGRAFTMENT; GRAFT FAILURE; HUMAN; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PURE RED CELL ANEMIA; RELAPSE; REVIEW; RISK ASSESSMENT;

EID: 84958214040     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000441507     Document Type: Review

References (53)

1. Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Kroger N, Farge-Bancel D, Gaspar HB, Marsh J, Mohty M, Peters C, Sureda A, Velardi A, Ruiz de Elvira C, Madrigal A; European Group for Bone Marrow Transplantation: Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant 2013;48:1161-1167.
2. Rydberg L: ABO-incompatibility in solid organ transplantation. Transfus Med 2001;11:325-342.
3. Rowley SD: Hematopoietic stem cell transplantation between red cell incompatible donor-recipient pairs. Bone Marrow Transplant 2001;28:315-321.
4. Worel N, Kalhs P: AB0-incompatible allogeneic hematopoietic stem cell transplantation. Haematologica 2008;93:1605-1607.
5. Bolan CD, Childs RW, Procter JL, Barrett AJ, Leitman SF: Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol 2001;112:787-795.
6. Kimura F, Sato K, Kobayashi S, Ikeda T, Sao H, Okamoto S, Miyamura K, Mori S, Akiyama H, Hirokawa M, Ohto H, Ashida H, Motoyoshi K, Japan Marrow Donor P: Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. Haematologica 2008;93:1686-1693.
7. Stussi G, Muntwyler J, Passweg JR, Seebach L, Schanz U, Gmur J, Gratwohl A, Seebach JD: Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;30:87-93.
8. Worel N, Greinix HT, Keil F, Mitterbauer M, Lechner K, Fischer G, Mayr W, Hocker P, Kalhs P: Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion 2002;42:1293-1301.
9. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A, Frauendorfer K; European Group for Bone Marrow Transplantation EBMT: The ebmt activity survey 2009:Trends over the past 5 years. Bone Marrow Transplant 2011;46:485-501.
10. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M, Frauendorfer K, Niederwieser D, Horowitz M, Kodera Y, Worldwide Network of Bone Marrow Transplantation: Hematopoietic stem cell transplantation: a global perspective. JAMA 2010;303:1617-1624.
11. Rowley SD, Donato ML, Bhattacharyya P: Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant 2011;46:1167-1185.
12. Gonzalez-Porras JR, Graciani IE, Perez-Simon JA, Martin-Sanchez J, Encinas C, Conde MP, Nieto MJ, Corral M: Prospective evaluation of a transfusion policy of D+ red blood cells into D- patients. Transfusion 2008;48:1318-1324.
13. Cid J, Lozano M, Fernandez-Aviles F, Carreras E, Pereira A, Mazzara R, Ordinas A: Anti-D alloimmunization after D-mismatched allogeneic hematopoietic stem cell transplantation in patients with hematologic diseases. Transfusion 2006;46:169-173.
14. Worel N, Bohm A, Rabitsch W, Leitner G, Mitterbauer M, Kalhs P, Mayr WR, Schwartz D, Greinix HT: Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning. Transfusion 2012;52:1348-1353.
15. Larghero J, Rea D, Esperou H, Biscay N, Maurer MN, Lacassagne MN, Ternaux B, Traineau R, Yakouben K, Dosquet C, Socie G, Gluckman E, Benbunan M, Marolleau JP: ABO-mismatched marrow processing for transplantation: results of 114 procedures and analysis of immediate adverse events and hematopoietic recovery. Transfusion 2006;46:398-402.
16. Nussbaumer W, Schwaighofer H, Gratwohl A, Kilga S, Schonitzer D, Nachbaur D, Niederwieser D: Transfusion of donor-type red cells as a single preparative treatment for bone marrow transplants with major ABO incompatibility. Transfusion 1995;35:592-595.
17. Worel N, Greinix HT, Supper V, Leitner G, Mitterbauer M, Rabitsch W, Fischer G, Rosenmayr A, Hocker P, Kalhs P: Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion 2007;47:1494-1502.
18. Bornhauser M, Ordemann R, Paaz U, Schuler U, Kompf J, Holig K, Ehninger G: Rapid engraftment after allogeneic ABO-incompatible peripheral blood progenitor cell transplantation complicated by severe hemolysis. Bone Marrow Transplant 1997;19:295-297.
19. Cohn CS: Transfusion support issues in hematopoietic stem cell transplantation. Cancer Control 2015;22:52-59.
20. Pulsipher MA, Boucher KM, Wall D, Frangoul H, Duval M, Goyal RK, Shaw PJ, Haight AE, Grimley M, Grupp SA, Kletzel M, Kadota R: Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009;114:1429-1436.
21. Worel N, Greinix HT, Schneider B, Kurz M, Rabitsch W, Knobl P, Reiter E, Derfler K, Fischer G, Hinterberger W, Hocker P, Kalhs P: Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 2000;40:543-550.
22. Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF, Barrett AJ, Childs RW: Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001;98:1687-1694.
23. Mielcarek M, Leisenring W, Torok-Storb B, Storb R: Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood 2000;96:1150-1156.
24. Lee JH, Lee KH, Kim S, Lee JS, Kim SH, Kwon SW, Kim WK: Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;25:179-184.
25. Schetelig J, Breitschaft A, Kroger N, Zabelina T, Ebell W, Bornhauser M, Haack A, Ehninger G, Salama A, Siegert W, Cooperative Transplantations Study Group: After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B. Transfusion 2005;45:779-787.
26. Stussi G, Halter J, Bucheli E, Valli PV, Seebach L, Gmur J, Gratwohl A, Schanz U, Passweg JR, Seebach JD: Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. Haematologica 2009;94:239-248.
27. Benjamin RJ, Connors JM, McGurk S, Churchill WH, Antin JH: Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 1998;4:151-156.
28. Helbig G, Stella-Holowiecka B, Wojnar J, Krawczyk M, Krzemien S, Wojciechowska-Sadus M, Markiewicz M, Wylezol I, Kopera M, Holowiecki J: Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies. Ann Hematol 2007;86:677-683.
29. Santamaria A, Sureda A, Martino R, Domingo-Albos A, Muniz-Diaz E, Brunet S: Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant 1997;20:1105-1107.
30. Verholen F, Stalder M, Helg C, Chalandon Y: Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 2004;73:441-446.
31. Helbig G, Stella-Holowiecka B, Krawczyk-Kulis M, Wojnar J, Markiewicz M, Wojciechowska-Sadus M, Kopera M, Kruzel T, Najda J, Nowak K, Holowiecki J: Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Haematologica 2005;90(suppl):ECR33.
32. Seebach JD, Stussi G, Passweg JR, Loberiza FR, Gajewski JL, Keating A, Goerner M, Rowlings PA, Tiberghien P, Elfenbein GJ, Gale RP, van Rood JJ, Reddy V, Gluckman E, Bolwell BJ, Klumpp TR, Horowitz MM, Ringden O, Barrett AJ; GVHD Working Committee of Center for International Blood and Marrow Transplant Research: ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 2005;11:1006-1013.
33. Dunstan RA: Status of major red cell blood group antigens on neutrophils, lymphocytes and monocytes. Br J Haematol 1986;62:301-309.
34. Cooling LLW, Kelly K, Barton J, Hwang D, Koerner TAW, Olson JD: Determinants of ABH expression on human blood platelets. Blood 2005;105:3356-3364.
35. Kollman C, Howe CWS, Anasetti C, Antin JH, Davies SM, Filipovich AH, Hegland J, Kamani N, Kernan NA, King R, Ratanatharathorn V, Weisdorf D, Confer DL: Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001;98:2043-2051.
36. Michallet M, Le QH, Mohty M, Prebet T, Nicolini F, Boiron JM, Esperou H, Attal M, Milpied N, Lioure B, Bordigoni P, Yakoub-Agha I, Bourhis JH, Rio B, Deconinck E, Renaud M, Chir Z, Blaise D: Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Exp Hematol 2008;36:535-544.
37. Canals C, Muniz-Diaz E, Martinez C, Martino R, Moreno I, Ramos A, Arilla M, Boto N, Pastoret C, Remacha A, Sierra J, Madoz P: Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning. Transfusion 2004;44:1603-1611.
38. Kanda J, Ichinohe T, Matsuo K, Benjamin RJ, Klumpp TR, Rozman P, Blumberg N, Mehta J, Sohn SK, Uchiyama T: Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies. Transfusion 2009;49:624-635.
39. Remberger M, Watz E, Ringden O, Mattsson J, Shanwell A, Wikman A: Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:675-682.
40. Bensinger WI, Buckner CD, Thomas ED, Clift RA: ABO-incompatible marrow transplants. Transplantation 1982;33:427-429.
41. Kim JG, Sohn SK, Kim DH, Baek JH, Lee KB, Min WS, Kim CC, Lee MH, Lee JJ, Chung IJ, Kim HJ, Lee JW: Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2005;35:489-495.
42. Worel N, Kalhs P, Keil F, Prinz E, Moser K, Schulenburg A, Mitterbauer M, Mannhalter C, Mayr WR, Schwarzinger I, Hocker P, Lechner K, Greinix HT: ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion 2003;43:1153-1161.
43. Bacigalupo A, Van Lint MT, Occhini D, Margiocco M, Ferrari G, Pittaluga PA, Frassoni F, Peralvo J, Lercari G, Carubia F, et al: ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 1988;45:1091-1094.
44. Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR: Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant 2001;7:620-630.
45. Ludajic K, Balavarca Y, Bickeböller H, Rosenmayr A, Fischer GF, Faé I, Kalhs P, Pohlreich D, Kouba M, Dobrovolna M, Greinix HT: Minor ABO-mismatches are risk factors for acute graft-versus-host disease in hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant 2009;15:1400-1406.
46. Gutierrez-Aguirre CH, Gomez-De-Leon A, Alatorre-Ricardo J, Cantu-Rodriguez OG, Gonzalez-Llano O, Jaime-Perez JC, Mancias-Guerra C, Flores-Jimenez JA, Gomez-Almaguer D: Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different? Transfusion 2014;54:1269-1277.
47. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Saso R, Tait D, Singhal S: Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? Bone Marrow Transplant 2002;29:853-859.
48. Erker CG, Steins MB, Fischer RJ, Kienast J, Berdel WE, Sibrowski W, Cassens U: The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation. Transfusion 2005;45:1382-1390.
49. Resnick IB, Tsirigotis PD, Shapira MY, Aker M, Bitan M, Samuel S, Abdul-Hai A, Ackerstein A, Or R, Slavin S: ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients. Biol Blood Marrow Transplant 2008;14:409-417.
50. Benjamin RJ, McGurk S, Ralston MS, Churchill WH, Antin JH: ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion 1999;39:179-187.
51. Rocha V, Gluckman E; Eurocord-Netcord registry and European Blood and Marrow Transplant group: Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 2009;147:262-274.
52. Blin N, Traineau R, Houssin S, Peffault de Latour R, Petropoulou A, Robin M, Larghero J, Ribaud P, Socie G: Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant 2010;16:1315-1323.
53. Ozkurt ZN, Yegin ZA, Yenicesu I, Aki SZ, Yagci M, Sucak GT: Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation. Transplant Proc 2009;41:3851-3858.